- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01200121
Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers
Double-blind, Placebo-controlled, Randomized Phase II-study Investigating the Efficacy of Bevacizumab for Symptom Control in Patients With Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers
Malignant ascites represents a severe clinical problem for physicians and patients being confronted with this common symptom of advanced-stage gastrointestinal cancer. Unfortunately, there is no standardized and evidence-based treatment for malignant ascites and therapies which are commonly being used are only temporarily effective. Newer modes of therapy, such as the application of the tri-functional antibody catumaxomab, are associated with significant side effects and are limited to patients in stages of good overall performance. Therefore, there is still an urgent need for more effective, longer-lasting, and less toxic modes of treatment for peritoneal effusions caused by gastrointestinal cancers.
Preclinical data strongly suggest that bevacizumab might be a very effective agent for the treatment of malignant ascites, which is in large part caused by the hyperpermeability-promoting factor VEGF. Emerging clinical results from cancer patients with malignant ascites treated with bevacizumab add further support to this idea. Bevacizumab has been tested in a variety of large clinical trials, has a good toxicity profile, and is effective in a number of human cancers underlying malignant ascites.
In the present study, Bevacizumab will be administered as an intraperitoneal infusion at an absolute standardized dosage of 400 mg. This dosage was chosen because it is comparable to the approved standard dosage for intravenous administration which was also used in both studies reporting the successful and safe intraperitoneal administration of Bevacizumab to patients with malignant ascites. Finally, a standardized dosage seems more practical in the particular patient population treated in this study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10967
- Vivantes Klinikum Am Urban, Klinik für Innere Medizin
-
Berlin, Germany, 12351
- VIVANTES Klinikum Neukölln, Onkologisches Zentrum Vivantes Süd
-
Berlin, Germany, 13353
- Charité (Campus Virchow-Klinikum), Med. Klinik mit Schwerpunkt Hämatologie und Onkologie
-
Berlin, Germany, 13585
- Vivantes Klinikum Spandau, Klinik für Innere Medizin
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg - Eppendorf, Onkologisches Zentrum
-
Hamburg, Germany, 20249
- MVZ für Innere Medizin in Hamburg-Eppendorf
-
-
Baden-Württemberg
-
Ludwigsburg, Baden-Württemberg, Germany, 71640
- Klinikum Ludwigsburg, Klinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie, Diabetologie
-
Wendlingen, Baden-Württemberg, Germany, 73240
- Onkologische Schwerpunktpraxis
-
-
Bayern
-
Deggendorf, Bayern, Germany, 94469
- Klinikum Deggendorf, Medizinische Klinik II
-
-
Berlin
-
Berlin-Zehlendorf, Berlin, Germany, 14195
- Medizinisches Versorgungszentrum, Onkologischer Schwerpunkt
-
-
Brandenburg
-
Potsdam, Brandenburg, Germany, 14467
- Ernst von Bergmann Klinikum, Zentrum für Hämatologie/Onkologie/Strahlenheilkunde
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60590
- Klinikum der J.W. Goethe-Univerisität Frankfurt, Klinik für Allgemein- und Viszeralchirurgie
-
Wetzlar, Hessen, Germany, 35578
- Klinikum Wetzlar-Braunfels, Medizinische Klinik II
-
-
Niedersachsen
-
Hannover, Niedersachsen, Germany, 30449
- Klinikum Region Hannover GmbH, Krankenhaus Siloah, Med. Klinik III (Hämatologie & Onkologie)
-
Hildesheim, Niedersachsen, Germany, 31135
- Onkologische Schwerpunktpraxis Hildesheim, Im Medicinum
-
-
Nordrhein-Westfalen
-
Essen, Nordrhein-Westfalen, Germany, 45136
- Kliniken Essen-Mitte, Klinik f. intern. Onkologie u. Hämatologie
-
Essen, Nordrhein-Westfalen, Germany, 45147
- Universitätsklinikum Essen, Klinik für Innere Medizin - Tumorforschung
-
Leverkusen, Nordrhein-Westfalen, Germany, 51375
- Klinikum Leverkusen gGmbH, Medizinische Klinik III
-
Mönchengladbach, Nordrhein-Westfalen, Germany, 41063
- Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus, Hämatologie/Onkologie/Gastroonkologie
-
Recklinghausen, Nordrhein-Westfalen, Germany, 45659
- Prosper-Hospital, Medizinische Klinik I
-
Würselen, Nordrhein-Westfalen, Germany, 52146
- Hämatologisch Onkologische Praxis Würselen
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Germany, 55131
- Johannes Gutenberg Universität, Universitätsklinikum, I. Medizinische Klinik und Poliklinik
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04103
- Universitätsklinikum Leipzig, Klinik für Gastroenterologie und Rheumatologie
-
Neustadt (Sachsen), Sachsen, Germany, 01844
- Internistische Praxis und Tagesklinik
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Germany, 06120
- Universitätslinikum der Martin-Luther Universität Halle-Wittenberg, Klinik für Innere Medizin IV
-
-
Schleswig-Holstein
-
Neumünster, Schleswig-Holstein, Germany, 24534
- Friedrich-Ebert-Krankenhaus GmbH, Klinik für Hämatologie, Onkologie/Nephrologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >= 18 years
- Written informed consent has been obtained prior to inclu¬sion into the study
- Patient is capable and willing to comply with the study
- Histologically confirmed esophageal, gastric, pancreatic, cholangiocellular, hepatocellular, or colorectal carcinoma
- Cytologically confirmed ascites OR diagnosis of an exsudate (total protein in ascites > 30 g/l) clinically suggestive for malignant ascites OR morphological diagnosis of peritoneal carcinosis by CT , MRT or ultrasound
- Ascites clinically judged as not responsive to conventional systemic therapies for primary malignancy
- Ascites clinically judged as not responsive to diuretics
- At the time of inclusion paracentesis required at least twice within past 4 weeks.
- Before inclusion of the patient into the study, a 4-week screening period will allow for a stringent evaluation of the patient regarding fulfillment of inclusion and exclusion criteria. Importantly, no treatments for malignant ascites other than paracentesis and diuretics are allowed during the 4-week screening period.
- ECOG performance score 0-3
- Life expectancy > 12 weeks
- Laboratory parameters:
Hematology
- Neutrophils > 1,500/µl
- Platelets > 100,000/µl
- Hemoglobin >= 9 g/dl or 5.59 mmol/l Hemastasiology
- INR <= 1.5 x ULN and aPTT <= 1.5 x ULN within past 7 dClinical chemistry
- Creatinine clearance > 30 ml/min, serum creatinine < 2.5 x ULN
- Serum bilirubin < 3.0 x ULN
- Alkaline phosphatase and transaminases < 3.0 x ULN (in case of liver metastases < 7 x ULN)
Urinalysis:
- Patients with < 2+ proteinuria on dipstick urinalysis.
- Patients with >= 2+ proteinuria on dipstick urinalysis, who demonstrate < 2.0 g of protein/24 h on 24-h urine collection
Exclusion Criteria:
- Concomitant malignancies other than gastrointestinal cancers (Patients with curatively treated basal and squamous cell carcino¬ma of the skin and / or in-situ carci¬noma of the cervix are eli¬gible).
- Bacterial peritonitis as indicated by laboratory results (neutrophil count > 250 / µl ascites) or clinical suspicion
- Hemorrhagic ascites (ascites hematocrit > 2%)
- Transudative ascites (total protein in ascites < 30 g/l)
- Parallel treatment with anti-tumor agents other than the study medication from inclusion into the study until safety follow-up. Chemotherapy may be continued if started before screening phase (- 4 weeks before inclusion). Parallel Treatment with Bevacizumab i.v. is not allowed.
- Therapy naïve patients
- Parallel treatment of ascites with measures other than para¬centesis, diuretics, and the study drugs from 4 weeks before inclusion into the study until safety follow-up.
- Patients with extensive metastases of the liver making up > 70% of the total liver mass
- Child C cirrhosis of the liver
- Occlusion or thrombosis of the portal vein.
- Evidence of current and symptomatic central nervous system (CNS) metas¬ta¬ses or spinal cord compression.
- Clinically significant cardiovascular diseases, e.g., un¬con¬trolled hypertension, uncontrolled arrhythmia, hemoptoe, cardiovascular accident within the last 6 months before treatment start, unstable angina, congestive heart failure (CHF) NYHA grade III/IV, symptomatic coronary heart disease, peripheral arterial disease stage >= II.
- History of fistula formation involving an internal organ (e.g. tracheo-oesophagal, bronchopleural, biliary, vagina and bladder)
- Major surgical procedure, open biopsy, or significant trau¬matic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study.
- Concomitant treatment with intravenous Bevacizumab for primary malignancy from inclusion into study until safety follow-up. Prior treatment with Bevacizumab for primary malignancy is not exclusionary.
- Serious non-healing wound, ulcer or bone fracture.
- Radiotherapy for purposes other than local control of symp¬toms.
- Evidence of bleeding diathesis or coagulopathy.
- Hematopoietic diseases.
- Known intra-abdominal inflammatory process or serious gastrointestinal ulceration.
- History of chronic intestinal diseases associated with severe diarrhea.
- Thrombo-embolic events or severe hemorrhage (<= 6 months before treatment start).
- Known hypersensitivity to the test drug Bevacizumab
- Evidence of any other disease, metabolic dysfunction, physi¬cal examination finding, or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug or puts the patient at high risk for treatment-related compli¬cations.
- With the only exception of full dose (INR > 1.5) oral coumarin-derived anticoagulants, the use of full dose anticoagulants is allowed as long as the INR or a PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for at least two weeks at the time of randomisation.
- Patients who participated within the last 30 days prior to enrolment in a clinical trial and received a non approved investigational drug (e.g. follow up within the trial is not exclusionary).
- Patients who have participated in this study before.
- Women, lactating, pregnant or of childbearing potential and fertile men not using a highly effective contraceptive method . [Women of childbearing potential must have a negative pregnancy test (serum ß HCG) within 7 days before the first dose of study drug].
- Patients who are committed to an institution by virtue of an order issued either by the judicial or the administra¬tive authorities (according to § 40 (1) 4 AMG).
- Patients who are underage or patients who are incapable to understand the aim, importance and consequences of the study and to give legal informed consent (according to § 40 (4) and § 41 (2) and (3) AMG).
- Patients with a history of a psychological illness or con¬di¬tion such as to interfere with the patient's ability to un¬der¬stand the requirements of the study.
- Patients who possibly are dependent on the sponsor or investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm A Bevacizumab
48 patients randomized into arm A will receive repeated intra¬peritoneal application of Bevacizumab
|
Patients will receive paracentesis as needed for symptom con¬trol.
In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed.
During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
Other Names:
|
PLACEBO_COMPARATOR: Arm B Placebo
26 patients randomized into arm B will receive repeated intra¬peritoneal application of Placebo
|
Patients will receive paracentesis as needed for symptom con¬trol.
In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed.
During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
paracentesis-free survival (ParFS)
Time Frame: one year
|
The first primary endpoint will consist of paracentesis-free survival (ParFS) which will be calculated as the time period between the initial puncture after randomization to the first subsequent paracentesis or other symptomatic treatments for ascites with the exception of diuretics or until death (whichever occurs first)
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Response (BR)
Time Frame: 12 weeks from 1st application
|
Best Response representing the longest period of time from one paracentesis until next paracentesis within the treatment period or, if longer, from the last paracentesis performed within the treatment period until first subsequent symptomatic treatment for ascites with the exception of diuretics (before end of the standard 4 week follow-up) or, if longer, from the last paracentesis performed within the treatment period until death (before end of the standard 4 week follow-up) or, if longer, from the last paracentesis performed within the treatment period until 4 week follow-up
|
12 weeks from 1st application
|
Volume of ascites
Time Frame: 12 weeks
|
Volume of ascites drained by routine paracentesis (ascites volume minus lavage volumes, if applicable)
|
12 weeks
|
Quality of life
Time Frame: 12 weeks
|
Quality of life as assessed by standardized questionnaires
|
12 weeks
|
Changes in ECOG performance status
Time Frame: baseline and 12 weeks
|
Calculation: 12 weeks minus baseline
|
baseline and 12 weeks
|
Pharmacokinetics of Bevacizumab and VEGF concentrations
Time Frame: 12 weeks
|
12 weeks
|
|
Proportions of patients with adverse events grades 3, 4, or 5.
Time Frame: 12 weeks
|
12 weeks
|
|
Proportions of patients with adverse events of special interest
Time Frame: 12 weeks
|
any grade of gastrointestinal perforation, gastrointestinal fistulas or other internal fistulas, wound-healing disturbances, hemorrhagic events and arterial thrombo-embolic events.
|
12 weeks
|
All adverse events
Time Frame: 12 weeks
|
12 weeks
|
|
Changes in laboratory values and vital signs.
Time Frame: baseline, every two weeks up to week 12
|
Calculation: Value from later timepoints minus baseline value
|
baseline, every two weeks up to week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Karin Jordan, Dr. med., Universitätslinikum der Martin-Luther Universität Halle-Wittenberg
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Ascites
- Gastrointestinal Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- AIO-SUP-0108
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Ascites
-
Second Affiliated Hospital of Soochow UniversityNot yet recruiting
-
Sichuan Clover Biopharmaceuticals, Inc.Completed
-
Sequana Medical N.V.CompletedMalignant AscitesGermany, Switzerland, United Kingdom
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Terminated
-
Eastern Regional Medical CenterTerminatedMalignant AscitesUnited States
-
West China HospitalRecruiting
-
Sequana Medical N.V.Withdrawn
-
Hospital Universitario Virgen MacarenaDelos ClinicalUnknownMalignant Ascites
-
Hui ting Xu,MDUnknown
-
Baylor College of MedicineGenentech, Inc.Withdrawn
Clinical Trials on Bevacizumab
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterRecruitingStage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)Active, not recruitingOvarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditionsUnited States, Canada
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7United States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small... and other conditionsUnited States